PL3018145T3 - Środki i sposoby leczenia chłoniaka rozlanego z dużych komórek B (DLBCL) - Google Patents

Środki i sposoby leczenia chłoniaka rozlanego z dużych komórek B (DLBCL)

Info

Publication number: PL3018145T3
Authority: PL; Poland
Prior art keywords: methods; treating dlbcl; dlbcl; treating
Prior art date: 2010-10-27

Application number

PL15195076T

Other languages

English (en)

Inventor

Gerhard Zugmaier

Dirk Nagorsen

Juergen Scheele

Original Assignee

Amgen Research (Munich) Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-27

Filing date

2011-10-27

Publication date

2018-09-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45023802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3018145(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-10-27 Application filed by Amgen Research (Munich) Gmbh filed Critical Amgen Research (Munich) Gmbh

2018-09-28 Publication of PL3018145T3 publication Critical patent/PL3018145T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)
Carbon And Carbon Compounds (AREA)

PL15195076T 2010-10-27 2011-10-27 Środki i sposoby leczenia chłoniaka rozlanego z dużych komórek B (DLBCL) PL3018145T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US40710710P	2010-10-27	2010-10-27
EP11787633.4A EP2632954B2 (en)	2010-10-27	2011-10-27	Means and methods for treating dlbcl
EP15195076.3A EP3018145B1 (en)	2010-10-27	2011-10-27	Means and methods for treating dlbcl

Publications (1)

Publication Number	Publication Date
PL3018145T3 true PL3018145T3 (pl)	2018-09-28

Family

ID=45023802

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL15195076T PL3018145T3 (pl)	2010-10-27	2011-10-27	Środki i sposoby leczenia chłoniaka rozlanego z dużych komórek B (DLBCL)
PL18164175T PL3412687T3 (pl)	2010-10-27	2011-10-27	Sposoby leczenia dlbcl
PL11787633T PL2632954T5 (pl)	2010-10-27	2011-10-27	Środki i sposoby leczenia DLBCL

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL18164175T PL3412687T3 (pl)	2010-10-27	2011-10-27	Sposoby leczenia dlbcl
PL11787633T PL2632954T5 (pl)	2010-10-27	2011-10-27	Środki i sposoby leczenia DLBCL

Country Status (32)

Country	Link
US (2)	US9192665B2 (pl)
EP (3)	EP2632954B2 (pl)
JP (3)	JP5997168B2 (pl)
KR (1)	KR101889995B1 (pl)
CN (2)	CN105251003B (pl)
AU (1)	AU2011322581B2 (pl)
CA (1)	CA2815119C (pl)
CL (1)	CL2013001138A1 (pl)
CR (1)	CR20130245A (pl)
CY (3)	CY1117155T1 (pl)
DK (3)	DK3412687T3 (pl)
EA (1)	EA032139B1 (pl)
ES (3)	ES2787044T3 (pl)
HK (1)	HK1188229A1 (pl)
HR (2)	HRP20151444T4 (pl)
HU (3)	HUE037786T2 (pl)
IL (3)	IL225924A (pl)
LT (2)	LT3412687T (pl)
MA (1)	MA34619B1 (pl)
ME (1)	ME02311B (pl)
MY (1)	MY163057A (pl)
NZ (2)	NZ609201A (pl)
PH (1)	PH12013500826A1 (pl)
PL (3)	PL3018145T3 (pl)
PT (3)	PT3018145T (pl)
RS (3)	RS60094B1 (pl)
SG (1)	SG189869A1 (pl)
SI (3)	SI2632954T2 (pl)
SM (3)	SMT201800319T1 (pl)
TR (1)	TR201808019T4 (pl)
UA (1)	UA111175C2 (pl)
WO (1)	WO2012055961A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1874821T3 (da)	2005-04-26	2013-07-08	Trion Pharma Gmbh	Kombination af antistoffer med glykokortikoider til behandling af kræft
ES2787044T3 (es) *	2010-10-27	2020-10-14	Amgen Res Munich Gmbh	Métodos para tratar LDCBG
EP3831386A1 (en)	2010-11-10	2021-06-09	Amgen Research (Munich) GmbH	Prevention of adverse effects caused by cd3 specific binding domains
JO3529B1 (ar) *	2013-02-08	2020-07-05	Amgen Res Munich Gmbh	مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
EP3057994B1 (en)	2013-10-15	2020-09-23	The Scripps Research Institute	Peptidic chimeric antigen receptor t cell switches and uses thereof
WO2016154621A1 (en)	2015-03-26	2016-09-29	The California Institute For Biomedical Research	SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
WO2016168773A2 (en)	2015-04-15	2016-10-20	The California Institute For Biomedical Research	Optimized pne-based chimeric receptor t cell switches and uses thereof
IL255697B2 (en)	2015-05-18	2023-11-01	Tcr2 Therapeutics Inc	Compositions and methods for tcr reprogramming using fusion proteins
IL299203A (en) *	2015-10-13	2023-02-01	Eureka Therapeutics Inc ׂ A Delaware Corp	Antibody factors specific for human differentiation group 19 and their uses
JP2019532017A (ja) *	2016-07-14	2019-11-07	フレッドハッチンソンキャンサーリサーチセンター	がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
JP7109789B2 (ja)	2016-08-02	2022-08-01	ティーシーアール２セラピューティクスインク．	融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
WO2018067993A1 (en)	2016-10-07	2018-04-12	TCR2 Therapeutics Inc.	Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP7149935B2 (ja)	2016-10-19	2022-10-07	ザスクリプスリサーチインスティテュート	ヒト化された標的化部分および／または最適化されたキメラ抗原受容体相互作用ドメインを有する、キメラ抗原受容体エフェクター細胞スイッチ、ならびにその使用
CN110177803A (zh)	2016-11-22	2019-08-27	T细胞受体治疗公司	用于使用融合蛋白进行tcr重新编程的组合物和方法
US10537585B2 (en)	2017-12-18	2020-01-21	Dexcel Pharma Technologies Ltd.	Compositions comprising dexamethasone
WO2019133847A1 (en)	2017-12-29	2019-07-04	Oncorus, Inc.	Oncolytic viral delivery of therapeutic polypeptides
WO2020099513A1 (en) *	2018-11-13	2020-05-22	Lipoxen Technologies Limited	Glycopolysialylation of blinatumomab
AU2020267378B2 (en) *	2019-05-03	2025-01-30	Kite Pharma, Inc.	Methods of administering chimeric antigen receptor immunotherapy
WO2020232247A1 (en)	2019-05-14	2020-11-19	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
US12221481B2 (en)	2019-05-21	2025-02-11	Novartis Ag	CD19 binding molecules and uses thereof
US12006366B2 (en)	2020-06-11	2024-06-11	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
CA3204063A1 (en) *	2020-12-04	2022-06-09	Morphosys Ag	Anti-cd19 combination therapy
EP4284512B1 (en)	2021-01-28	2025-03-26	Regeneron Pharmaceuticals, Inc.	Compositions and methods for treating cytokine release syndrome
KR20250004700A (ko)	2022-04-11	2025-01-08	리제너론 파마슈티칼스 인코포레이티드	보편적 종양 세포 사멸을 위한 조성물 및 방법
WO2024173830A2 (en)	2023-02-17	2024-08-22	Regeneron Pharmaceuticals, Inc.	Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH02500329A (ja)	1987-05-21	1990-02-08	クリエイテイブ・バイオマリキユールズ・インコーポレーテツド	ターゲット化多機能蛋白質
KR100508289B1 (ko)	1998-04-21	2005-08-17	마이크로메트 에이지	Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
US7635472B2 (en)	2003-05-31	2009-12-22	Micromet Ag	Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
AU2004293182B2 (en)	2003-11-28	2010-02-18	Amgen Research (Munich) Gmbh	Compositions comprising polypeptides
KR101289537B1 (ko)	2005-02-15	2013-07-31	듀크 유니버시티	항-ｃｄ19 항체 및 종양학에서 이의 용도
DK1874821T3 (da) *	2005-04-26	2013-07-08	Trion Pharma Gmbh	Kombination af antistoffer med glykokortikoider til behandling af kræft
CN101331151A (zh) *	2005-12-16	2008-12-24	麦克罗梅特股份公司	治疗肿瘤性疾病的方式和方法
ES2532124T3 (es) *	2005-12-16	2015-03-24	Amgen Research (Munich) Gmbh	Medios y procedimientos para el tratamiento de enfermedades tumorales
EP2066349B1 (en)	2006-09-08	2012-03-28	MedImmune, LLC	Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
CN109456410B (zh)	2007-04-03	2022-01-28	安进研发（慕尼黑）股份有限公司	跨物种特异性CD3-ε结合结构域
AU2009313040B2 (en) *	2008-11-07	2015-07-09	Amgen Research (Munich) Gmbh	Treatment of acute lymphoblastic leukemia
JP6092625B2 (ja)	2009-10-27	2017-03-08	アムゲンリサーチ（ミュンヘン）ゲーエムベーハー	ＣＤ１９ｘＣＤ３二重特異性抗体を投与するための投与計画
ES2787044T3 (es) *	2010-10-27	2020-10-14	Amgen Res Munich Gmbh	Métodos para tratar LDCBG

2011
- 2011-10-27 ES ES18164175T patent/ES2787044T3/es active Active
- 2011-10-27 SI SI201130709T patent/SI2632954T2/sl unknown
- 2011-10-27 DK DK18164175.4T patent/DK3412687T3/da active
- 2011-10-27 EP EP11787633.4A patent/EP2632954B2/en active Active
- 2011-10-27 JP JP2013535437A patent/JP5997168B2/ja active Active
- 2011-10-27 LT LTEP18164175.4T patent/LT3412687T/lt unknown
- 2011-10-27 RS RS20200368A patent/RS60094B1/sr unknown
- 2011-10-27 RS RS20160027A patent/RS54525B2/sr unknown
- 2011-10-27 CN CN201510672546.6A patent/CN105251003B/zh active Active
- 2011-10-27 ES ES11787633T patent/ES2563439T5/es active Active
- 2011-10-27 SG SG2013026828A patent/SG189869A1/en unknown
- 2011-10-27 NZ NZ609201A patent/NZ609201A/en unknown
- 2011-10-27 PT PT151950763T patent/PT3018145T/pt unknown
- 2011-10-27 PH PH1/2013/500826A patent/PH12013500826A1/en unknown
- 2011-10-27 SI SI201131489T patent/SI3018145T1/en unknown
- 2011-10-27 US US13/881,889 patent/US9192665B2/en active Active
- 2011-10-27 EA EA201390387A patent/EA032139B1/ru not_active IP Right Cessation
- 2011-10-27 LT LTEP15195076.3T patent/LT3018145T/lt unknown
- 2011-10-27 PT PT117876334T patent/PT2632954E/pt unknown
- 2011-10-27 SM SM20180319T patent/SMT201800319T1/it unknown
- 2011-10-27 PL PL15195076T patent/PL3018145T3/pl unknown
- 2011-10-27 PL PL18164175T patent/PL3412687T3/pl unknown
- 2011-10-27 HU HUE15195076A patent/HUE037786T2/hu unknown
- 2011-10-27 WO PCT/EP2011/068851 patent/WO2012055961A1/en active Application Filing
- 2011-10-27 ES ES15195076.3T patent/ES2675299T3/es active Active
- 2011-10-27 ME MEP-2015-213A patent/ME02311B/me unknown
- 2011-10-27 SI SI201131861T patent/SI3412687T1/sl unknown
- 2011-10-27 DK DK15195076.3T patent/DK3018145T3/en active
- 2011-10-27 DK DK11787633.4T patent/DK2632954T4/da active
- 2011-10-27 EP EP18164175.4A patent/EP3412687B1/en not_active Revoked
- 2011-10-27 RS RS20180624A patent/RS57260B1/sr unknown
- 2011-10-27 UA UAA201306486A patent/UA111175C2/uk unknown
- 2011-10-27 HU HUE11787633A patent/HUE027678T2/en unknown
- 2011-10-27 CN CN201180063222.2A patent/CN103459425B/zh active Active
- 2011-10-27 AU AU2011322581A patent/AU2011322581B2/en active Active
- 2011-10-27 HU HUE18164175A patent/HUE048639T2/hu unknown
- 2011-10-27 CA CA2815119A patent/CA2815119C/en active Active
- 2011-10-27 EP EP15195076.3A patent/EP3018145B1/en active Active
- 2011-10-27 PL PL11787633T patent/PL2632954T5/pl unknown
- 2011-10-27 MA MA35841A patent/MA34619B1/fr unknown
- 2011-10-27 NZ NZ701715A patent/NZ701715A/en unknown
- 2011-10-27 SM SM20200232T patent/SMT202000232T1/it unknown
- 2011-10-27 MY MYPI2013001269A patent/MY163057A/en unknown
- 2011-10-27 PT PT181641754T patent/PT3412687T/pt unknown
- 2011-10-27 KR KR1020137013384A patent/KR101889995B1/ko active Active
- 2011-10-27 TR TR2018/08019T patent/TR201808019T4/tr unknown
2013
- 2013-04-24 IL IL225924A patent/IL225924A/en active IP Right Grant
- 2013-04-25 CL CL2013001138A patent/CL2013001138A1/es unknown
- 2013-05-27 CR CR20130245A patent/CR20130245A/es unknown
2014
- 2014-02-14 HK HK14101399.9A patent/HK1188229A1/xx unknown
2015
- 2015-10-16 US US14/885,404 patent/US10696744B2/en active Active
- 2015-12-31 HR HRP20151444TT patent/HRP20151444T4/hr unknown
2016
- 2016-01-29 CY CY20161100083T patent/CY1117155T1/el unknown
- 2016-02-17 SM SM201600050T patent/SMT201600050B/xx unknown
- 2016-06-01 JP JP2016110083A patent/JP6254220B2/ja active Active
2017
- 2017-11-29 JP JP2017228716A patent/JP6522722B2/ja active Active
- 2017-12-05 IL IL256110A patent/IL256110B/en active IP Right Grant
2018
- 2018-05-16 CY CY20181100508T patent/CY1120227T1/el unknown
- 2018-06-05 HR HRP20180882TT patent/HRP20180882T1/hr unknown
- 2018-07-25 IL IL260774A patent/IL260774B/en active IP Right Grant
2020
- 2020-05-08 CY CY20201100425T patent/CY1123251T1/el unknown

Also Published As

Publication number	Publication date
CN103459425B (zh)	2015-11-25
US20130287778A1 (en)	2013-10-31
ES2563439T3 (es)	2016-03-15
EA032139B1 (ru)	2019-04-30
HRP20151444T4 (hr)	2021-08-20
LT3018145T (lt)	2018-05-10
CN105251003B (zh)	2019-08-02
SMT201600050B (it)	2016-04-29
PT3412687T (pt)	2020-04-03
HK1188229A1 (zh)	2014-04-25
IL225924A (en)	2017-12-31
HUE048639T2 (hu)	2020-08-28
HUE037786T2 (hu)	2018-09-28
EA201390387A1 (ru)	2013-10-30
SMT201800319T1 (it)	2018-07-17
RS54525B1 (en)	2016-06-30
AU2011322581B2 (en)	2015-04-23
SI3018145T1 (en)	2018-08-31
IL225924A0 (en)	2013-06-27
HUE027678T2 (en)	2016-11-28
ES2675299T3 (es)	2018-07-10
KR20140019298A (ko)	2014-02-14
DK3018145T3 (en)	2018-05-28
CY1117155T1 (el)	2017-04-05
JP6254220B2 (ja)	2017-12-27
WO2012055961A1 (en)	2012-05-03
CN103459425A (zh)	2013-12-18
JP6522722B2 (ja)	2019-05-29
CR20130245A (es)	2013-09-20
JP5997168B2 (ja)	2016-09-28
NZ609201A (en)	2015-01-30
EP3018145A1 (en)	2016-05-11
UA111175C2 (uk)	2016-04-11
NZ719768A (en)	2021-07-30
PT2632954E (pt)	2016-02-03
US20160208001A1 (en)	2016-07-21
US9192665B2 (en)	2015-11-24
SI3412687T1 (sl)	2020-07-31
EP2632954A1 (en)	2013-09-04
TR201808019T4 (tr)	2018-06-21
PH12013500826A1 (en)	2013-06-17
HRP20180882T1 (hr)	2018-07-27
EP3412687B1 (en)	2020-03-18
RS57260B1 (sr)	2018-08-31
NZ701715A (en)	2016-05-27
SG189869A1 (en)	2013-06-28
LT3412687T (lt)	2020-07-27
ES2563439T5 (es)	2022-02-04
IL256110A (en)	2018-02-28
RS60094B1 (sr)	2020-05-29
CN105251003A (zh)	2016-01-20
CY1120227T1 (el)	2018-12-12
PL2632954T3 (pl)	2016-05-31
PT3018145T (pt)	2018-05-17
PL3412687T3 (pl)	2020-07-27
CL2013001138A1 (es)	2014-11-14
CA2815119A1 (en)	2012-05-03
ME02311B (me)	2016-06-20
KR101889995B1 (ko)	2018-08-20
JP2013540799A (ja)	2013-11-07
US10696744B2 (en)	2020-06-30
EP2632954B1 (en)	2015-11-25
MA34619B1 (fr)	2013-10-02
AU2011322581A1 (en)	2013-05-09
CY1123251T1 (el)	2021-10-29
DK2632954T3 (en)	2016-02-01
EP3412687A1 (en)	2018-12-12
ES2787044T3 (es)	2020-10-14
SI2632954T1 (sl)	2016-02-29
SMT202000232T1 (it)	2020-07-08
MY163057A (en)	2017-08-15
IL256110B (en)	2018-08-30
CA2815119C (en)	2023-01-10
PL2632954T5 (pl)	2021-11-02
IL260774B (en)	2019-02-28
HRP20151444T1 (hr)	2016-01-29
SI2632954T2 (sl)	2021-11-30
EP2632954B2 (en)	2021-07-07
DK3412687T3 (da)	2020-05-11
EP3018145B1 (en)	2018-04-04
RS54525B2 (sr)	2021-08-31
DK2632954T4 (da)	2021-08-09
JP2018039838A (ja)	2018-03-15
JP2016164192A (ja)	2016-09-08

Publication	Publication Date	Title
HRP20180882T1 (hr)	2018-07-27	Sredstva za i postupci liječenja dlbcl
EP2619715A4 (en)	2016-08-10	METHOD AND DEVICES FOR CONTEXT DEFINITION
AP2013006680A0 (en)	2013-01-31	Methods and compounds for treating paramyxoviridaevirus infections
PL2649391T3 (pl)	2017-10-31	Urządzenie do suszenia i sposoby suszenia
GB201003190D0 (en)	2010-04-14	Apparatus and method
ZA201303423B (en)	2015-06-24	Compositions and methods for treating myelofibrosis
ZA201304360B (en)	2014-02-26	Method and device for treating biomass
SI2525953T1 (sl)	2014-06-30	Postopek in naprava za pripravo in razstrupljanje
GB201002083D0 (en)	2010-03-24	Apparatus for improving and/or maintaining numerical ability
GB2483684B (en)	2014-05-07	Range determination apparatus and method
PT2627818T (pt)	2021-04-07	Método e disposição para tratamento de pasta
GB201005885D0 (en)	2010-05-26	Apparatus and method
GB201003255D0 (en)	2010-04-14	Apparatus and method
GB201105826D0 (en)	2011-05-18	Apparatus and method
GB201021057D0 (en)	2011-01-26	Method and apparatus
GB201006393D0 (en)	2010-06-02	An apparatus and associated methods
GB201011768D0 (en)	2010-08-25	Apparatus and methods for operation
GB201000806D0 (en)	2010-03-03	Apparatus and methods
GB201010290D0 (en)	2010-08-04	Apparatus and methods
GB201016993D0 (en)	2010-11-24	Apparatus and method
GB201012886D0 (en)	2010-09-15	Apparatus and method
GB201010399D0 (en)	2010-08-04	Apparatus and method
GB201010267D0 (en)	2010-08-04	Apparatus and method
GB201008082D0 (en)	2010-06-30	Apparatus and method
GB201003264D0 (en)	2010-04-14	Apparatus and method